gene sequencing instruments and lab supplies, is joining with two partners—the Phoenix-based Translational Genomics Research Institute and U.S. Oncology in Woodands, TX—to sequence the genomes of 14 women with an aggressive form of breast cancer.
—Neurocrine Biosciences (NASDAQ: [[ticker:NBIX]]), the San Diego biotech company developing treatments for neurological and endocrine disorders, raised gross proceeds of about $20 million in a stock offering.
—Amylin Pharmaceuticals (NASDAQ: [ticker:AMLN]]) and partners Waltham, MA-based Alkermes (NASDAQ: [[ticker:ALKS]]) and Eli Lilly (NYSE: [[ticker:LLY]]) are awaiting the March 12 deadline for an FDA decision on their application to market a once-weekly version of the diabetes drug exenatide (Byetta).
—Acadia Pharmaceuticals (NASDAQ: [[ticker:ACAD]]) and partner Biovail (NYSE: [[ticker:BVF]]), a Canadian biotech, provided an update on the development plans for the experimental drug pimavanserin.
—Cardium Therapeutics (NYSE Amex: [[ticker:CXM]]) raised $5 million from institutional investors in a direct offering, according to a press release.